LEXINGTON, Mass., June 21, 2012 /PRNewswire/ -- Imprivata®, Inc., the leader in secure access management and collaboration, announced today that Imprivata OneSign® has received a score of 88.4 in the KLAS "2012 Mid-Term Performance Review: Software & Services" report. The report states that Imprivata scored 6 or more points above the software category average and between 3 and 6 points above the Single Sign-On (SSO) market area average. Reflecting its popularity within the company's fast-growing, avid customer base, OneSign was among the top 7 products -- out of the 718 rated this year -- to demonstrate the largest increase in score since its strong performance in the "2011 Best in KLAS Awards: Software & Services" report published this past December.
The steady increase in Imprivata's approval rating is also evidenced by the recent Frost & Sullivan Customer Value Enhancement award commending the company for OneSign's role in speeding EMR adoption, and a growing list of customers, many of whom are gaining recognition for achieving Stage 6 and Stage 7 on the HIMSS Electronic Medical Record Adoption Model (EMRAM). Imprivata's scores are further validated by the highest "Konfidence" level awarded by KLAS; this means that the company meets the greatest threshold for the number of unique SSO customers who have provided feedback to KLAS.
"Imprivata's success can be attributed to listening and understanding our customers' needs," said Ed Gaudet, Chief Marketing Officer at Imprivata. "Our KLAS rating is the best independent measure of performance from customers, and we're proud of our continued high ratings."
As healthcare organizations continue to sharpen their focus on meeting Meaningful Use deadlines and accelerating Electronic Health Records (EHRs) adoption, the demand for Imprivata OneSign has continued to rise steeply. The seamless security capabilities of OneSign have been proven to improve clinician productivity, increase data security and enhance the care delivery process.
KLAS is a research firm specializing in monitoring and reporting the performance of healthcare vendors. KLAS' mission is to improve delivery of healthcare, by independently measuring vendor performance for the benefit of healthcare provider partners, consultants, investors, and vendors by collecting accurate, honest and impartial provider experiences. Working together with executives from more than 4,500 hospitals and more than 2,500 clinics, KLAS delivers timely reports, trends, and statistics, which provide a solid overview of vendor performance in the industry. KLAS measures performance of software, professional services, medical equipment, and infrastructure vendors. For more information, go to www.KLASresearch.com, email marketing@KLASresearch.com, or call 1-800-920-4109 to speak with a KLAS representative. Follow KLAS on Twitter at www.twitter.com/KLASresearch.
With more than 2 million users and 900 healthcare customers, Imprivata is the #1 provider of secure access and collaboration solutions for healthcare. By strengthening user authentication, streamlining application access and simplifying compliance reporting across multiple computing environments, customers realize improved workflows, increased security and compliance with government regulations.
Imprivata has received numerous product awards and top review ratings from leading industry publications and analysts, including the Frost & Sullivan 2012 NA Customer Value Enhancement Award for healthcare IT, a Strong Positive rating in Gartner's 2011 Marketscope for ESSO, the #1 ranking in the KLAS SSO Performance report and the #1 rating in 2010 Best in KLAS and Category Leaders report. Headquartered in Lexington, Mass., Imprivata partners with over 200 resellers, and serves the access security and collaboration needs of customers around the world. For more information, please visit www.imprivata.com or follow us on Twitter at @Imprivata.
All Imprivata products are trademarks of Imprivata, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.